Evidence map›Paper›PMID 39963364›Full record

ArticleFrontiers in pharmacology2024

Leveraging AI to automate detection and quantification of extrachromosomal DNA to decode drug responses.

Kohen Goble, Aarav Mehta, Damien Guilbaud, Jacob Fessler, Jingting Chen, William Nenad, Christina G Ford, Oliver Cope, Darby Cheng, William Dennis and 4 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Kohen Goble *Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Aarav Mehta *Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Damien GuilbaudIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Jacob FesslerDepartment of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Jingting ChenDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
William NenadComputational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Christina G FordIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Oliver CopeIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Darby ChengDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
William DennisIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Nithya GurumurthyIntegrative Program for Biological and Genome Sciences (IBGS), University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Yue WangDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Kriti ShuklaDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Elizabeth Brunk *Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Funding

UNC PREP in the Biomedical Sciences - Administrative SupplementR25GM089569 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBINSON, DONITA L, RODRIGUEZ-ROMAGUERA, JOSE · 2010 to 2024
$5.6M
NIGMS NIH HHS R25 GM089569
6 · The paper itself

Abstract

Introduction: Traditional drug discovery efforts primarily target rapid, reversible protein-mediated adaptations to counteract cancer cell resistance. However, cancer cells also utilize DNA-based strategies, often perceived as slow, irreversible changes like point mutations or drug-resistant clone selection. Extrachromosomal DNA (ecDNA), in contrast, represents a rapid, reversible, and predictable DNA alteration critical for cancer's adaptive response. Methods: In this study, we developed a novel post-processing pipeline for automated detection and quantification of ecDNA in metaphase Fluorescence in situ Hybridization (FISH) images, leveraging the Microscopy Image Analyzer (MIA) tool. This pipeline is tailored to monitor ecDNA dynamics during drug treatment. Results: Our approach effectively quantified ecDNA changes, providing a robust framework for analyzing the adaptive responses of cancer cells under therapeutic pressure. Discussion: The pipeline not only serves as a valuable resource for automating ecDNA detection in metaphase FISH images but also highlights the role of ecDNA in facilitating swift and reversible adaptation to epigenetic remodeling agents such as JQ1.

Indexed as

computer visioncytogeneticsdeep neural networksdouble minute chromosomesecDNAextrachromosomal DNAfluorescence in situ hybridizationmachine learning

Identifiers

PMID39963364
PMCPMC11830698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.